Metabolic health.

The Three Metabolic Failure Modes: Incretin, Hepatic, and Mitochondrial

Metabolic disease converges on three cellular failure modes. Incretin signaling failure (Semaglutide) drives appetite dysregulation and glycemic instability in established obesity and type 2 diabetes. Hepatic lipid metabolism disruption (Tesamorelin) drives visceral adiposity and fatty liver progression bridging hormonal dysregulation and metabolic disease. Mitochondrial energy dysregulation (MOTS-c) drives cellular-level insulin resistance preceding clinical metabolic syndrome — the upstream research target with the furthest gap from clinical validation.

TIER 1 — Semaglutide (GLP-1 RA): FDA-Approved Metabolic Evidence Anchor

Semaglutide is a GLP-1 receptor agonist that mimics endogenous glucagon-like peptide-1, the incretin hormone released by gut L-cells in response to food intake. GLP-1 stimulates insulin secretion (glucose-dependent), suppresses glucagon, slows gastric emptying, and reduces appetite centrally via hypothalamic GLP-1 receptor activation. The STEP 1 trial (PMID: 33567185, N Engl J Med 2021) demonstrated 14.9% mean body weight reduction with once-weekly semaglutide 2.4mg versus 2.4% with placebo over 68 weeks. Semaglutide is FDA-approved for obesity (Wegovy 2021) and type 2 diabetes (Ozempic 2017) — the most broadly approved compound on this page. Including it as the evidence anchor reflects honest editorial judgment: for the metabolic health goal, GLP-1 receptor agonists have the strongest human RCT evidence available. Omitting semaglutide to favor less-evidenced research peptides would compromise the evidence standard this platform maintains.

TIER 2 — Tesamorelin (FDA-Approved): Hepatic Metabolism and Visceral Fat

Tesamorelin (Egrifta, FDA-approved 2010) bridges both the hormonal-optimization and metabolic-health pages: it stimulates pulsatile GH release (hormonal mechanism) with downstream effects primarily on hepatic lipid metabolism and visceral adiposity (metabolic outcome). The JCI Insight 2020 paper (PMID: 32701508) documented Tesamorelin producing significant hepatic transcriptomic changes in HIV-associated NAFLD patients, including downregulation of pro-inflammatory pathways and changes in lipid metabolic gene expression. Tesamorelin reduces visceral adipose tissue specifically, the adipose depot most associated with metabolic risk. Evidence boundary: the FDA-approved indication is HIV-lipodystrophy specifically; the general metabolic application for visceral fat reduction in non-HIV populations has more limited published evidence.

TIER 3 — MOTS-c: Mitochondrial Retrograde Metabolic Regulation

MOTS-c is a 16-amino acid peptide encoded in the mitochondrial genome that functions as a retrograde metabolic signal. Its primary mechanism is AMPK activation, shifting cellular energy allocation from anabolic growth toward oxidative metabolism, fat burning, and insulin sensitization. MOTS-c is a pre-disease metabolic regulator addressing mitochondrial energy sensing dysfunction that precedes clinical insulin resistance. The founding Cell Metabolism 2015 paper (PMID: 25738459) established MOTS-c as a mitochondrially-encoded AMPK activator reducing obesity and insulin resistance in animal models. The 2023 Metabolites review (PMID: 36677050) documented MOTS-c functionally preventing multiple metabolic disorder phenotypes. Evidence boundary: primarily preclinical. MOTS-c circulating levels decline with age in humans; whether exogenous supplementation restores clinically meaningful metabolic effects is not confirmed by published RCTs.

Research Evidence for Metabolic Health Peptides

This page has the widest evidence gap between compounds of any page on this platform: Semaglutide has NEJM-published phase 3 RCT evidence with nearly 2000 subjects; MOTS-c has animal models and mechanistic reviews. Honest evidence ranking requires acknowledging this disparity.

Semaglutide: Flagship Human RCT Evidence

The STEP 1 trial (PMID: 33567185, N Engl J Med 2021) is one of the highest-quality obesity intervention trials in the modern era. The 1961-participant phase 3 RCT demonstrated 14.9% mean body weight loss with semaglutide 2.4mg weekly versus 2.4% with placebo over 68 weeks, with clinically meaningful improvements in cardiometabolic risk factors. The SELECT cardiovascular outcomes trial subsequently demonstrated semaglutide reducing major adverse cardiovascular events in people with obesity and established cardiovascular disease — extending the evidence beyond weight reduction to cardiovascular outcome benefit. Evidence quality hierarchy: semaglutide evidence is in a different class from any research peptide on this platform.

Tesamorelin: Hepatic Transcriptomics and Visceral Adiposity

The JCI Insight 2020 paper (PMID: 32701508) analyzed hepatic gene expression changes in HIV-associated NAFLD patients treated with Tesamorelin, documenting significant modulation of pro-inflammatory gene networks, lipid biosynthesis pathways, and fibrosis-associated signaling. Tesamorelin phase 3 trials for HIV lipodystrophy demonstrated significant reduction in trunk fat versus placebo. Visceral fat reduction is the metabolic outcome most directly associated with cardiometabolic risk improvement because visceral adipose tissue drives hepatic lipid flux, adipokine-mediated inflammation, and insulin resistance.

MOTS-c: Preclinical Metabolic Evidence

The Lee et al. 2015 Cell Metabolism paper (PMID: 25738459) established MOTS-c as a mitochondrially-encoded AMPK activator that reduces obesity and insulin resistance in animal models through metabolic homeostasis mechanisms. The 2023 Metabolites review (PMID: 36677050) synthesized subsequent MOTS-c metabolic disease prevention research, confirming the AMPK-mediated insulin sensitizing mechanism across multiple metabolic disorder models. Human evidence: MOTS-c circulating levels decline with age and metabolic disease severity in humans — an observational association. Exogenous supplementation producing equivalent human benefits is not confirmed by published clinical trials.

The AOD9604 Evidence Gap

AOD9604 (hGH fragment 177-191) entered clinical development for obesity in the early 2000s but development was discontinued. PubMed evidence is limited to animal model studies; no completed human RCT was published. AOD9604 belongs in the alternatives section with explicit disclosure that the published evidence base is preclinical and that the clinical development program did not produce published RCT data.

Tracking Metabolic Health Outcomes

Metabolic health has the most directly measurable outcomes of any goal on this platform.

• HOMA-IR Every 6 Weeks: HOMA-IR (fasting glucose x fasting insulin / 405) is the primary insulin sensitivity proxy. Target below 1.5 (optimal); 1.5-2.5 (mild insulin resistance); above 2.5 (significant insulin resistance). MOTS-c AMPK activation and Tesamorelin visceral fat reduction both improve insulin sensitivity. For Semaglutide protocols, HbA1c provides the 3-month average glycemic metric.
• Lipid Panel Every 8 Weeks: Target triglycerides below 150 mg/dL; HDL above 60 mg/dL. Rising HDL and falling triglycerides are the most sensitive lipid markers for improving metabolic health on any of these protocols.
• Body Composition (DXA) Every 8 Weeks: Weight alone does not differentiate fat mass reduction from lean mass loss. DXA provides total fat mass, lean mass, and visceral adipose tissue separately. For Tesamorelin (visceral fat target) and Semaglutide (total fat loss) protocols, DXA or waist circumference trending is essential. Target waist circumference below 94cm male, 80cm female.
• hs-CRP Every 8 Weeks: Visceral adiposity is the primary driver of elevated inflammatory baseline in metabolic syndrome. Tesamorelin visceral fat reduction and MOTS-c AMPK activation both target the inflammatory component. Target hs-CRP below 1.0 mg/L (low cardiovascular risk); above 3.0 mg/L is high-risk.
• ALT and AST Every 8 Weeks (Tesamorelin protocols): For Tesamorelin targeting hepatic metabolism: ALT and AST provide accessible liver health markers. Tesamorelin hepatic transcriptomic evidence (PMID: 32701508) demonstrates anti-inflammatory hepatic gene expression changes; improvement in liver enzymes would be consistent with mechanism engagement in NAFLD-spectrum patients. Normal ALT and AST below 40 U/L.

Alternative Approaches to Metabolic Health

The metabolic health alternatives section must be honest about the evidence hierarchy: the highest-evidence interventions for metabolic health are not peptides. This page already includes semaglutide precisely because honest evidence ranking demands it.

The Behavioral Foundation: Highest-Evidence Metabolic Interventions

The interventions with the strongest human evidence for metabolic health improvement are behavioral: (1) Caloric restriction and dietary pattern improvement - Mediterranean diet has the most human RCT data for metabolic risk reduction; (2) Aerobic exercise at moderate-to-vigorous intensity for 150 or more minutes per week - the single most effective AMPK activator available, directly paralleling the MOTS-c mechanism; (3) Resistance training for skeletal muscle mass maintenance - muscle tissue is the primary site of glucose disposal; (4) Sleep optimization 7-9 hours - one week of sleep restriction to 5 hours significantly worsens insulin sensitivity in human studies. Any metabolic peptide protocol should be built on top of these behavioral foundations.

Metformin: The AMPK Benchmark

Metformin activates AMPK through hepatic Complex I inhibition - the same AMPK pathway that MOTS-c activates through mitochondrial retrograde signaling. Metformin has a 70-year safety record, comprehensive human evidence database, and is first-line pharmacological treatment for type 2 diabetes in most international guidelines. It is available as a generic prescription at low cost. For anyone considering MOTS-c for metabolic disease prevention, Metformin represents the evidence-benchmarked pharmacological comparison: more evidence, lower cost, prescription-required, pharmaceutical grade versus research peptide.

AOD9604: Honest Evidence Gap Disclosure

AOD9604 is a synthetic peptide fragment of human growth hormone (amino acids 177-191) developed as a selective lipolytic compound. Preclinical evidence demonstrated selective fat reduction in animal obesity models. The compound entered human clinical trials in the early 2000s for obesity but development was discontinued and no completed phase 3 RCT data appeared in peer-reviewed literature. PubMed evidence is limited to animal model studies. AOD9604 is commercially available as a research peptide and frequently marketed with claims that exceed the available evidence. Honest assessment: mechanistically plausible lipolytic mechanism, no published human RCT evidence, discontinued pharmaceutical development.

Tirzepatide (GIP/GLP-1 Dual Agonist): The Next-Class Comparison

Tirzepatide (Mounjaro for T2D, Zepbound for obesity, FDA-approved 2022/2023) is a dual agonist at GIP and GLP-1 receptors producing greater weight loss than GLP-1 agonism alone. Phase 3 trial data demonstrates 20-22% body weight reduction with tirzepatide 15mg weekly. Direct head-to-head trials show tirzepatide superiority over semaglutide for weight loss. Tirzepatide belongs in the alternatives section rather than primary tiers because it is even further from the research peptide context than semaglutide. The evidence hierarchy is clear: tirzepatide exceeds semaglutide exceeds research peptides for weight loss outcome evidence.